← All trials
NCT05238337
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2022
- Primary completion
- Mar 24, 2022
- Completion date
- Mar 24, 2022
- First posted
- Feb 14, 2022
- Last posted
- Aug 30, 2022
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pyramid BiosciencesLead sponsor
- Pyramid BiosciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.